重症监护室血管升压药依赖性休克的辅助米多君治疗:系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE、Ovid Embase、CINAHL和Cochrane图书馆至2023年9月14日,纳入7项随机对照试验(6项进入汇总分析)和10项观察性研究(4项进入汇总分析),评估口服米多君对比安慰剂或常规治疗对ICU血管升压药依赖性休克患者的疗效与安全性。结果显示,辅助米多君可能缩短ICU住院时间和静脉升压药支持时间,可能降低ICU死亡率和住院死亡率,但证据确定性低至极低,且试验序贯分析提示ICU住院时间和静脉升压药持续时间所需样本量未达到。米多君可能增加心动过缓风险。作者认为,尽管可能对患者中心结局有益,但因不良事件风险增加,需进一步大规模研究指导其ICU常规使用。
要点
- 辅助口服米多君可能缩短ICU住院时间(证据确定性低),对住院住院时间影响的证据确定性低。
- 米多君可能缩短静脉升压药支持持续时间、降低ICU死亡率和住院死亡率。
- 米多君可能增加心动过缓风险。
- 试验序贯分析提示ICU住院时间和静脉升压药持续时间所需样本量未达到,导致GRADE评估为不精确。
- 观察性数据汇总所有结局的证据确定性均为极低。
适用人群与场景
- 纳入标准:1)血管升压药依赖性休克患者;2)在ICU进行;3)评估口服米多君治疗对比安慰剂或常规治疗;4)评估至少一项感兴趣结局。
红旗征与不能漏的情况
- 米多君可能增加心动过缓风险。
研究设计与关键结果
- 研究设计:系统评价与Meta分析,检索MEDLINE、Ovid Embase、CINAHL和Cochrane图书馆数据库至2023年9月14日。
- 纳入研究:7项随机对照试验(6项进入汇总分析)和10项观察性研究(4项进入汇总分析)。
- 主要结果:辅助米多君可能缩短ICU住院时间(证据确定性低),对住院住院时间影响的证据确定性低;可能缩短静脉升压药支持持续时间、降低ICU死亡率和住院死亡率。
- 观察性数据汇总:所有感兴趣结局的证据确定性均为极低。
- 试验序贯分析:ICU住院时间和静脉升压药持续时间所需样本量未达到,导致GRADE评估为不精确。
- 安全性:米多君可能增加心动过缓风险。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机对照试验和观察性研究。
- 证据确定性:随机对照试验数据中,ICU住院时间证据确定性低,住院住院时间证据确定性低;观察性数据汇总所有结局证据确定性均为极低。
- 局限:试验序贯分析提示ICU住院时间和静脉升压药持续时间所需样本量未达到,导致GRADE评估为不精确;观察性数据汇总所有结局证据确定性极低;需进一步大规模研究以指导ICU常规使用。
对床旁实践的改变
- 作者认为,辅助米多君可能改善患者中心结局,但因不良事件风险增加,需进一步大规模研究以指导和规范其在ICU的常规使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To summarize the efficacy of midodrine as an adjunctive therapy in critically ill patients. Safety of midodrine was assessed as a secondary outcome.
DATA SOURCES: We performed a systematic review and meta-analysis using a peer-reviewed search strategy combining the themes of vasopressor-dependent shock, critical care, and midodrine and including MEDLINE, Ovid Embase, CINAHL, and Cochrane library databases until September 14, 2023.
STUDY SELECTION: We included studies if they: 1) included patients with vasopressor-dependent shock, 2) were performed in the ICU, 3) evaluated oral midodrine therapy compared with placebo or usual care, and 4) evaluated one of the outcomes of interest.
DATA EXTRACTION: We extracted data independently in duplicate using standardized data abstraction forms, which included the following specific variables: patient characteristics, age, sex, type of ICU, etiology of shock, number of patients, study inclusion and exclusion criteria, and geographical location. We also captured the type, dose, and duration of IV vasopressors, any cointervention used, and outcome data.
DATA SYNTHESIS: We identified seven randomized controlled trials (six included in the pooled analysis) and ten observational studies (four included in the pooled analysis) that met eligibility criteria. Adjunctive midodrine may decrease ICU length of stay (LOS) and there is low certainty of effect on hospital LOS. Midodrine may decrease IV vasopressor support duration, ICU mortality, and hospital mortality. Pooled observational data was based on very low certainty data for all outcomes of interest. The trial sequential analysis-informed required sample size was not met for ICU LOS or IV vasopressor duration and this contributed to Grading of Recommendations, Assessment, Development, and Evaluations assessments of imprecision for both outcomes.
CONCLUSIONS: Adjunctive midodrine may decrease ICU LOS, duration of IV vasopressor therapy, and mortality in critically ill patients. However, required sample sizes was not met to determine our outcomes of interest. Midodrine may increase risk of bradycardia. While midodrine may provide benefit for patient-centered outcomes, due to increased risk of adverse events, further large-scale studies are needed to inform and guide its routine use in the ICU.
参考来源
- Kilcommons SJ, Hammal F, Kamaleldin M, et al. Adjunctive Midodrine Therapy for Vasopressor-Dependent Shock in the ICU: A Systematic Review and Meta-Analysis. Crit Care Med. 2024. PMID: 39631091. doi:10.1097/CCM.0000000000006519
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。